A detailed history of Northern Trust Corp transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 44,013 shares of RPHM stock, worth $73,941. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,013
Previous 117,860 62.66%
Holding current value
$73,941
Previous $177,000 58.19%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.34 - $1.7 $98,954 - $125,539
-73,847 Reduced 62.66%
44,013 $74,000
Q2 2024

Aug 14, 2024

BUY
$1.51 - $1.9 $8,632 - $10,862
5,717 Added 5.1%
117,860 $177,000
Q1 2024

May 14, 2024

SELL
$1.59 - $1.74 $7,150 - $7,824
-4,497 Reduced 3.86%
112,143 $186,000
Q4 2023

Feb 13, 2024

SELL
$1.34 - $8.43 $4,845 - $30,482
-3,616 Reduced 3.01%
116,640 $186,000
Q3 2023

Nov 13, 2023

BUY
$5.44 - $8.13 $109,752 - $164,022
20,175 Added 20.16%
120,256 $916,000
Q2 2023

Aug 11, 2023

BUY
$5.44 - $10.5 $462,666 - $893,014
85,049 Added 565.79%
100,081 $656,000
Q1 2023

May 15, 2023

BUY
$2.44 - $6.42 $7,625 - $20,062
3,125 Added 26.25%
15,032 $89,000
Q2 2022

Aug 12, 2022

SELL
$1.96 - $3.04 $110,773 - $171,811
-56,517 Reduced 82.6%
11,907 $31,000
Q1 2022

May 13, 2022

BUY
$2.94 - $9.07 $14,338 - $44,234
4,877 Added 7.67%
68,424 $201,000
Q4 2021

Feb 08, 2022

BUY
$6.07 - $9.68 $27,424 - $43,734
4,518 Added 7.65%
63,547 $544,000
Q3 2021

Nov 15, 2021

SELL
$6.28 - $11.07 $59,145 - $104,257
-9,418 Reduced 13.76%
59,029 $439,000
Q2 2021

Aug 13, 2021

BUY
$7.78 - $15.0 $532,517 - $1.03 Million
68,447 New
68,447 $639,000

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.